Which class of medications is first-line for reducing cardiovascular events in patients with established atherosclerotic disease and type 2 diabetes?

• A. Beta blockers
• B. SGLT2 inhibitors (with CV benefit) or GLP-1 receptor agonists (with weight loss benefits) depending on patient profile
• C. Calcium channel blockers
• D. Statins alone

Answer: (B)

In patients who have both established atherosclerotic disease and type 2 diabetes, the aim is to lower cardiovascular risk with therapies that have proven cardiovascular benefits, not just improve blood sugar. Among glucose-lowering options, agents with demonstrated cardiovascular outcome improvements are favored. SGLT2 inhibitors have strong evidence showing reduced major adverse cardiovascular events and, notably, reduced hospitalizations for heart failure and protection of kidney function. GLP-1 receptor agonists also reduce cardiovascular events and come with the added benefit of weight loss, which can be particularly helpful in type 2 diabetes with ASCVD. Which agent to choose can depend on the patient’s profile: if heart failure risk or CKD is a major concern, an SGLT2 inhibitor might be preferred; if weight management is a priority or if there’s substantial ASCVD risk that GLP-1 receptor agonists have shown benefits for, a GLP-1 receptor agonist with CV benefit is appropriate.

Beta blockers and calcium channel blockers address symptoms and blood pressure but don’t provide the same proven reduction in cardiovascular events in this specific high-risk population. Statins remain essential for lipid-related risk reduction, but the question centers on antidiabetic therapies with independent cardiovascular benefits, for which these newer agents are best suited.